Ondan

Quick links to important sections

Ondan

Method of action: Anti-Abstinence, Antiemetic

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ondan

Property Description
Active ingredient Ondansetron
Form Tablets (ODT, film-coated), Oral solution, Injectable solution
Pharmacological class Antiemetic, Selective 5-HT3 Receptor Antagonist
Common purpose Prevention and relief of nausea and vomiting
Origin Synthetic carbazole compound

What Type of Medicine is Ondan?

The medicine known as Ondan is a prescription-only product defined by its sole active ingredient, Ondansetron. It is classified within the broad pharmacological class of antiemetics, which are agents used for the prevention or relief of nausea and vomiting. Specifically, Ondansetron is a highly selective agent designated as a 5-HT3 receptor antagonist. This synthetic compound, chemically derived from the carbazole family, is a standard therapeutic agent. The active substance is typically found in its salt form, Ondansetron hydrochloride dihydrate, serving as a single active ingredient product.

What is Ondansetron's General Purpose?

The general purpose of Ondansetron is to provide effective control over feelings of sickness by targeting the body's emesis signaling system. Its primary function is to perform a blocking action against the neurotransmitter serotonin (5-HT) at its specific 5-HT3 receptor sites, which are key triggers for the vomiting reflex. As a selective antagonist, Ondansetron blocks these receptors located both in the gut and the brain's Chemoreceptor Trigger Zone. This selective mechanism ensures that the drug's core benefit is the inhibition of the vomiting reflex, utilized in scenarios where gastrointestinal stress is anticipated.

Available Forms of Ondansetron

Ondansetron is manufactured in distinct pharmaceutical preparations to ensure flexibility in delivery across various clinical needs. These high-level dosage forms include film-coated tablets and the specialized orally disintegrating tablets (ODT), both suitable for oral administration. The ODT form represents a specific feature, allowing patients who are experiencing nausea to receive the medication without the requirement of swallowing a traditional pill. For situations requiring rapid systemic effects, the drug is also prepared as a sterile injectable solution, which permits administration via the intravenous (IV) or intramuscular (IM) route of administration.

Regulatory References

  1. WHO Model List of Essential Medicines

What side effects are possible with Ondan?

Possible Side Effects and Safety Information

Ondan (ondansetron) is generally well-tolerated, but like all medications, it can cause side effects. These can range from common and mild to rare and serious. It is important to discuss all pre-existing medical conditions and current medications with a healthcare provider before starting treatment with Ondan.


Common Side Effects

The most frequently reported side effects, typically affecting more than 1 in 100 people, often include:

  • Headache
  • Constipation or diarrhea
  • Fatigue or a general feeling of malaise
  • A sensation of warmth or flushing

These side effects are generally mild and may resolve as the body adjusts to the medication. If they persist or become bothersome, consult your doctor.


Serious Safety Concerns

Though rare, Ondan can cause serious side effects that require immediate medical attention. You should contact emergency services or your doctor right away if you experience any of the following:

Concern Key Symptoms
Heart Rhythm Changes Fast, slow, or irregular heartbeat; dizziness, fainting, or chest pain. Ondan can prolong the QT interval, a condition that may lead to a dangerous heart rhythm.
Serotonin Syndrome Agitation, confusion, hallucinations, fast heart rate, fever, excessive sweating, muscle stiffness, twitching, or loss of coordination. This risk is increased when taken with other medications that affect serotonin levels.
Allergic Reactions Hives, skin rash, swelling of the face, lips, tongue, or throat, or difficulty breathing (anaphylaxis).

Ondan should be used with caution in patients with a history of long QT syndrome, severe liver impairment, or an existing bowel obstruction, as it may mask symptoms.

Overdose and Emergency Response

Official Overdose Profile and Emergency Action

The regulatory profile for Ondansetron overdose is defined by specific risks to the cardiovascular and central nervous systems. Documented clinical manifestations observed in overdose scenarios include transient visual disturbances, such as sudden temporary blindness (amaurosis), as well as severe constipation, hypotension (low blood pressure), and faintness. In rare cases, seizures have also been reported.

The most serious outcomes associated with increased exposure are primarily cardiac. These include dose-dependent QT interval prolongation, which significantly raises the risk of a potentially fatal abnormal heart rhythm known as Torsade de Pointes. Other severe outcomes involve arrhythmias and the possibility of Serotonin Syndrome.

Immediate medical attention must be sought for a suspected overdose. Official guidance mandates that emergency services be contacted immediately if the person has collapsed, experienced a seizure, or has difficulty breathing. Overdose management is limited to appropriate supportive therapy, as no specific antidote is known. Continuous ECG monitoring is recommended for patients with existing risk factors for cardiac toxicity, such as underlying heart conditions or electrolyte imbalances.

Therapeutic Uses of Ondan

Ondansetron is commonly used to help with symptoms related to systemic imbalance, focusing on relieving and preventing intense nausea and repeated vomiting that arise in specific clinical contexts marked by heightened systemic burden. Its benefit is commonly used to help with easing pronounced symptoms that create noticeable physiological strain and may interfere with daily functioning. Specifically, the medication is generally used for symptoms related to cancer treatments and surgical procedures.


Therapeutic Support in Key Clinical Domains

The medication is applied across domains where short-term symptom management is appropriate, including sickness caused by chemotherapy, radiation therapy, and postoperative nausea and vomiting (PONV). It is also considered relevant for severe, persistent vomiting in pediatric patients with acute gastroenteritis. The primary purpose of the medication is to provide support that helps ease the overall symptom burden, particularly during episodes where symptoms become temporarily overwhelming, such as in conditions involving episodic or fluctuating manifestations.


Quick Fact: Relief for Acute Sickness
Ondansetron is relevant for easing symptoms linked to symptoms of increased neurological or muscular activity in conditions characterized by periods of heightened symptoms, such as those experienced post-surgery or during aggressive cancer treatment.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who can and cannot use Ondan?

The population eligibility for Ondan (Ondansetron) is strictly defined by regulatory documentation.

Absolute Contraindications

The medicine is contraindicated and must not be used by patients with a known hypersensitivity to the drug or by those receiving concomitant apomorphine. Use must also be avoided in patients diagnosed with congenital long QT syndrome due to the risk of severe cardiac events.

Age and Organ Restrictions

For children, Ondan is approved for Chemotherapy-Induced Nausea and Vomiting (CINV) at 6 months of age or older and for Postoperative Nausea and Vomiting (PONV) at 1 month of age or older. In older adults, the initial intravenous dose is restricted and must not exceed 8 mg in patients aged 75 years or older. Patients with severe hepatic impairment must adhere to a strict regulatory maximum total daily dose of 8 mg. Conversely, patients with renal impairment do not require any dose adjustment. Use is not recommended during the first trimester of pregnancy or while breastfeeding.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Ondansetron is defined by specific regulatory requirements regarding co-administration with other substances and classes of medicinal products.


Formal Restrictions and Contraindications

Co-administration of Ondansetron with Apomorphine is strictly contraindicated. This is a mandatory restriction based on documented reports of a significant risk for profound hypotension and loss of consciousness associated with combining these two agents.


Documented Drug-Drug Interactions

Interactions are primarily classified based on pharmacokinetic interference and combined pharmacodynamic effects.

  • Exposure-Altering Agents (PK): Strong hepatic enzyme inducers, specifically Phenytoin, Carbamazepine, and Rifampin, significantly increase the clearance of Ondansetron. This pharmacokinetic interaction results in decreased Ondansetron blood concentrations. The medicine is primarily metabolized by CYP enzymes, including CYP3A4, CYP2D6, and CYP1A2.
  • Pharmacodynamic Risks (PD): Concomitant use with other serotonergic drugs carries a regulatory warning for the potential development of Serotonin Syndrome. Combining Ondansetron with medicines known to prolong the QT interval may increase the risk of cardiac rhythm changes.
  • Non-Interacting Agents: Official documents note that Ondansetron does not alter the respiratory depressant effects of Alfentanil or the degree of neuromuscular blockade produced by Atracurium.

Food and Population Notes

The oral bioavailability of the medication is officially documented as slightly enhanced by the presence of food. Additionally, in patients with severe hepatic impairment, the clearance of Ondansetron is substantially decreased, a population-specific consideration that affects maximum allowed daily exposure.

Mechanism of Action

Ondan's mechanism is based on the selective antagonism of the Serotonin 5-HT₃ receptor, which mediates a key impulse within the emetic reflex arc. The drug acts at two critical anatomical sites: the vagal afferent nerve terminals in the gut and the Chemoreceptor Trigger Zone (CTZ) in the brainstem. By blocking the 5-HT₃ receptors in both the periphery and the central nervous system, the drug interrupts the transmission and reception of the key pro-emetic signal.

The primary physiological consequence is the modulation of the molecular cascade where serotonin is the dominant signaling mediator. When emetic triggers cause the release of serotonin from the gastrointestinal enterochromaffin cells, Ondan's receptor blockade prevents this neurotransmitter from binding and activating the nerve impulse. This action modifies the early molecular steps that shape systemic physiological outcomes, contributing to the suppression of afferent neural discharge within the targeted pathways.

This mechanism is defined by its high specificity for the 5-HT₃ receptor. This specificity confines the mechanism's action to the serotonin pathway, and consequently, it exhibits negligible activity in conditions driven by other signaling mediators, such as those involving the vestibular system.

Dosage and Administration Information

How Ondan is Used

Ondansetron is administered according to a precise, event-dependent protocol that establishes the specific dose, route, and timing based on the emetogenic intensity of the patient’s planned treatment. The primary goal of its use is prophylaxis, meaning the initial dose must be administered at a defined interval before the start of the nausea-inducing event, such as chemotherapy or surgery.


Administration Routes and Forms

Ondansetron is available for use via both the Oral route, available as film-coated tablets, oral solutions, and Orally Disintegrating Tablets (ODT), and the Parenteral route, which includes Intravenous (IV) or Intramuscular (IM) injection. The IV route is typically reserved for use in supervised settings, requiring the injectable solution to be diluted in compatible fluids and infused over a specified duration, such as over 15 minutes for chemotherapy-induced nausea and vomiting (CINV). ODTs require handling with dry hands and must be allowed to dissolve on the tongue without chewing.


Dosing Patterns and Follow-up

Dosing schedules are highly specific to the clinical context. For highly emetogenic chemotherapy (HEC), the regimen may involve a single oral dose of 24 mg or a weight-based IV regimen administered in three fractional doses on the day of treatment. For moderately emetogenic chemotherapy (MEC) or radiotherapy (RINV), an initial 8 mg dose is followed by a regimen of 8 mg every 8 hours for a short-term duration, typically continuing for 1 to 5 days after the treatment course to manage delayed symptoms. A single 4 mg IV or IM dose is common for the prevention or treatment of established postoperative nausea and vomiting (PONV).


Population-Specific Use

Specific limitations exist for certain populations. In adult patients with severe hepatic impairment, the total daily dose must be reduced and not exceed 8 mg by any route. For pediatric patients, IV dosing is calculated based on Body Surface Area (BSA) or weight.

Recent Clinical Evidence

Research evidence / Overview of studies for Ondan

Evidence for Use in Chemotherapy-Induced Nausea and Vomiting (CINV)

Ondan was extensively studied in research exploring how symptoms change over time associated with cancer treatment. Researchers conducted many Randomized Controlled Trials (RCTs) and gathered the data into systematic reviews and meta-analyses to explore short-term symptom changes in adults and children receiving chemotherapy.

Research examined outcomes related to physical discomfort by monitoring the study endpoint defined as "Complete Response," which recorded periods with no vomiting and no use of rescue antiemetic medication. Findings describe patterns observed in the studies related to symptom measurement during both the acute phase (0–24 hours) and the delayed phase (up to 120 hours) following chemotherapy.

Evidence for Use in Postoperative Nausea and Vomiting (PONV)

The role of Ondan in symptom management after surgery was evaluated in a large number of short-term RCTs and systematic reviews. The studies included diverse groups of adult and pediatric patients who were at risk of experiencing postoperative sickness.

Regulatory-cited research highlights changes measured during the study period, describing patterns related to both vomiting and the need for rescue anti-sickness medicines within the first 24 hours after an operation. Research suggests that outcomes describing nausea may be more variable than those related to vomiting. Follow-up durations were typically limited to the hours immediately following surgery.

What Research Gaps and Uncertainties Remain

The majority of regulatory-cited studies for all indications involved short-term follow-up durations. Data for extended-duration use in chronic or recurring sickness conditions remain insufficient. Comparative evidence is lacking in certain areas, such as radiation-induced sickness (RINV) and treating established, breakthrough symptoms (symptoms that occur despite initial preventive treatment). Furthermore, results apply only to the populations studied, and research does not determine whether an individual will respond similarly.

Key Studies & References

  1. Ondansetron - StatPearls - NCBI Bookshelf
  2. Cost-effectiveness of oral ondansetron for children with acute gastroenteritis in primary care: a randomised controlled trial

Frequently Asked Questions (FAQ)

Common questions about Ondan (FAQ)

Q: How quickly should I expect Ondan to start working after taking it?

According to official regulatory information, the active ingredient in Ondan typically reaches its highest concentration in the blood approximately 1.5 hours after a person takes an oral dose. This time frame can help give an idea of when the medication is working to prevent or manage sickness.

Q: How long do the effects of one dose of Ondan typically last?

The time it takes for half of the medication to be eliminated from the body, known as the terminal phase half-life, is about 3.9 hours in adults. This half-life is used to determine how frequently the medicine needs to be taken to maintain a therapeutic effect.

Q: Does Ondan cause drowsiness or make it difficult to drive?

Official product information indicates that side effects like drowsiness and a feeling of tiredness have been reported. Official information suggests that feeling dizzy is possible, so individuals may need to assess their alertness before performing tasks that require concentration.

Q: Is it common for people to feel constipated while taking Ondan?

Yes, regulatory documents list constipation as a frequently reported side effect. In some clinical trials, it occurred in up to 11% of patients, indicating it is one of the more common adverse effects observed.

Q: Can I take Ondan with over-the-counter pain relievers like ibuprofen or Tylenol?

The official drug label focuses on specific interactions with prescription medicines that affect the heart or serotonin levels. There is no formal contraindication or interaction warning listed for common over-the-counter pain relievers. For personalized guidance on combining Ondan with other products, consulting a healthcare provider is recommended.

Q: Can I take Ondan if I am already taking blood thinners?

The regulatory drug label does not specifically list blood thinners (anticoagulants) as a class of medication that interacts with Ondan. Interactions are primarily focused on drugs that affect the heart rhythm or serotonin levels in the body.

Q: Does Ondan interact with common cold or allergy medications?

The main focus of drug interaction warnings in regulatory documents is on medications metabolized by liver enzymes (CYP enzymes) or those that can increase the risk of heart rhythm problems or Serotonin Syndrome. Many common cold and allergy medicines do not fall into these major interaction categories.

Q: Can Ondan be taken with antacids like Tums or Rolaids?

Official pharmacokinetic studies show that taking Ondan with food can slightly enhance its absorption. If there are concerns about taking Ondan with specific antacids, it is best to discuss them with a healthcare professional, especially since some antacids can affect mineral balance in the body.

Q: Can I consume alcohol in moderation while I am taking Ondan?

Official regulatory documents do not list a formal drug-drug interaction between Ondan and alcohol. However, individuals should be aware that consuming alcohol can independently cause or worsen sickness, which may complicate the assessment of Ondan's effects.

Q: Does Ondan help with motion sickness, or is it only for specific types of nausea?

Due to its specific mechanism, which targets signals from the gut and the brainstem, regulatory information suggests Ondan is not typically effective against motion sickness, which is mediated by the inner ear (vestibular system). The approved uses are for chemotherapy, radiation, and post-operative sickness.

Q: Are there any specific foods or drinks I should avoid while taking Ondan?

Regulatory documents indicate that the oral absorption of the medicine is slightly increased when taken with food. However, no specific foods or drinks are listed in the official product information that must be strictly avoided while taking Ondan.

Q: Is there a maximum number of days or doses I can safely take Ondan?

Ondan is approved for short-term uses, such as preventing sickness from chemotherapy or surgery, where the regimen is typically limited to a single dose or a period of up to five days. It is not approved for long-term or chronic use, and usage duration should be discussed with a prescriber.

Q: What happens if I miss a dose of Ondan and remember later?

Official patient information often describes a standard procedure for a missed dose: if remembered soon after the scheduled time, the dose can typically be taken. However, if it is almost time for the next scheduled dose, the missed one is generally skipped. It is generally recommended not to take a double dose to compensate for a missed one.

Q: Can children take Ondan for stomach upset, and what is the general recommendation?

Regulatory bodies have approved Ondan for specific uses in children, such as preventing sickness from chemotherapy (age 6 months and older) or surgery (age 1 month and older). It is not officially approved for general stomach upset or gastroenteritis.

Q: Does Ondan have any known interaction with herbal supplements like ginger or St. John's Wort?

Official drug information has identified a potential interaction risk with the herbal supplement St. John's Wort, which may increase the risk of Serotonin Syndrome when combined with Ondan. Any use of herbal products should be disclosed to a healthcare provider.

Q: Is it possible to become dependent on Ondan if used frequently?

Regulatory documents include a section on Drug Abuse and Dependence. While studies have been performed, the overall potential for dependence in humans is not a stated concern on the primary drug label.

Q: Can Ondan be used for severe morning sickness during pregnancy (non-advisory)?

Ondan is officially approved for sickness related to chemotherapy and surgery. Its use for nausea and vomiting of pregnancy is considered an off-label use by the FDA, meaning it is not specifically approved for this condition, although a physician may decide to prescribe it based on clinical judgment.

Q: Do I need a prescription to get Ondan, or can I buy it over the counter?

Ondan, which contains the active ingredient ondansetron, is officially classified as a prescription-only drug in all its forms.

Q: Does Ondan cause weight gain or weight loss in people who use it?

The regulatory documents do not list consistent weight gain or weight loss as a common or serious side effect. Changes in appetite or 'poor oral intake' have been mentioned in rare metabolic adverse event reports, but no consistent effect is documented.

Q: What is the shelf life of Ondan, and how should I store it?

Ondan products should generally be stored at Controlled Room Temperature (typically 20 C to 25 C) and protected from light. The specific shelf life for a product batch is printed on the packaging. The injectable solution, once diluted, has a limited use window, often up to 24 hours.

Q: Is there a generic version of Ondan available, and is it as effective?

Yes, Ondansetron is the generic name for Ondan and is widely available. Regulatory agencies require that all generic medicines demonstrate the same quality, strength, stability, and therapeutic effectiveness as the brand-name product.

Q: Does Ondan have any effect on appetite?

Official safety data includes mention of rare reports of poor oral intake or changes in appetite as part of metabolic side effects. However, a consistent or widespread effect on appetite is not described in common adverse event listings.

Q: Are there different strengths or dosages of Ondan available?

Yes, Ondan is manufactured in various strengths. Oral tablets are typically available in 4 mg, 8 mg, and 24 mg strengths. Orally Disintegrating Tablets (ODT) usually come in 4 mg and 8 mg strengths, in addition to the injectable solutions.

Q: Do clinical trials support the use of Ondan in pediatric patients?

Yes, regulatory approvals for children are supported by clinical studies. Safety and effectiveness have been established for chemotherapy- and surgery-related sickness in infants as young as one month old, based on well-controlled adult studies and supplementary pediatric data.

How should Ondan be stored and disposed of?

Storage and Disposal of Ondansetron Products

Storage of Ondansetron products must adhere strictly to regulatory conditions, primarily requiring storage at Controlled Room Temperature, typically 20 C to 25 C. All forms must be kept in their original containers, which should be tightly closed, and mandatory protection from light is required for most preparations. The oral solution should also be stored away from excess moisture.

For the injectable solution, storage in a refrigerator is an approved option, but once diluted, the solution has a limited use period and should not be used beyond 24 hours. If a precipitate appears in the vial, it must be resolubilized by shaking vigorously. All medication must be kept out of the sight and reach of children.

Disposal must follow local regulations for pharmaceutical waste. Unused or expired product should not be thrown away via wastewater or household waste; a pharmacist should be consulted for proper disposal guidance.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ondan found in:

A-Z Index: